[153]
Dr. Hayakawa testified that he was surprised when he received the results of the mortality tests for levofloxacin because in his experience there was a trend that together with high antimicrobial activity came high toxicity. (Hayakawa Affidavit at para. 60, AR, v. 4, Tab 6, p. 725.)